Ten Eleven Translocation Gene 2 (TET2) Polymorphism In Acute Myeloid Leukemia

  • Nahla A.M. Hamed Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt
  • Ayda Aly Nazer Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt
  • Mona Wagdy Ayad Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Egypt
  • Tamer Sabah Sadiq Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt
Keywords: Acute myeloid leukemia, TET2, gene mutations, polymorphism

Abstract

Background: Acute myeloid leukemia (AML) is a genetically heterogeneous disease in which somatic mutations that disturb cellular growth, proliferation, and differentiation accumulate in hematopoietic progenitor cells. TET methylcytosine dioxygenase 2 (TET2) gene mutations have been recognized in AML and appeared to have an adverse prognostic indicator in cytogenetically normal AML patients. Methods: The study was designed to detect the TET2 single nucleotide polymorphism (SNP rs 6843141) in AML patients. Thirty one AML patients were enrolled in this study, median age was 41 years and male to female ratio was 1:1. Twenty five age and sex matched persons were considered a control group. Patients underwent thorough routine workup, Real time PCR for TET2 SNP polymorphism expression with an ABI Prism Genamp 7500 using peripheral blood c-25767872-10, rs 6843141 (UK) was done for all cases and controls. Result: TET2 polymorphism SNP rs 6843141 was detected in all AML cases with 26 (83.9%) patients showing homozygous pattern and 5 (16.1%) patients showing heterozygous pattern while the control group was mostly wild type (11 patients, 44 %) and heterozygous group (11 patients, 44 %), p<0.001.  The highest homozygous pattern (19 out of 26 patients, 73%) was present in AML M1, M2 and M5 subtypes, which are the commonest encountered subtypes among our cases. Fifteen out of 27 AML patients were cytogenetically normal (55.5%). TET2 polymorphism showed higher bone marrow blast percentage among homozygous group, p=0.015. Conclusion: TET2 SNP rs 6843141 polymorphism is common among Egyptian AML cases irrespective of their cytogenetic abnormality.

References

Smith BD, Sung L. Acute myeloid leukemia. blood 2013;5(18):481-9.
2. Suhag VS, Malkovska V, Solomon SR. Acute myeloid leukemia.. In: Griffin P. Rodgers and Neal S. Young (eds). Bethesda Handbook of Clinical Hematology. Lippincott: Williams & Wilkins 2013;131-47.
3. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012;120(18):e83-e92.
4. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011;29(5):475-86.
5. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-5.
6. Solary E, Bernard O, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014;28(3):485-96.
7. Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012;139:1895-902.
8. Liu W-J, Tan X-H, Luo X-P, Guo B-P, Wei Z-J, Ke Q, et al. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leukemia & lymphoma 2014;55(12):2691-8.
9. Hamed N, El Halawani N, Kassem H, Ayad M, Dammag E. TET2 expression in a cohort of Egyptian acute myeloid leukemia patients. The Egyptian Journal of Haematology 2015;40(4):159-65.
10. Li M-J, Yang Y-L, Lee N-C, Jou S-T, Lu M-Y, Chang H-H, et al. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia. Journal of the Formosan Medical Association 2016;115(9):801-6.
11. Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, et al. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children/'s Oncology Group. Leukemia 2015;29(12):2424-6.
12. Gaidzik VI, Paschka P, Spath D, Habdank M, Kohne CH, Germing U, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012;30(12):1350-7.
13. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2011;26:934-42.
14. Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2011;29(10):1373-81.
15. Chou W-C, Chou S-C, Liu C-Y, Chen C-Y, Hou H-A, Kuo Y-Y, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118(14):3803-10.
16. Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010;116(7):1132-5.
17. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014;28(3):485-96.
18. Schnittger S, Nadarajah N, Alpermann T, Eder C, Kohlmann A, Kuznia S, et al. Comparison of mutation patterns between diagnosis and relapse in 556 adult patients with AML shows high variability of stability. Blood 2013;122(21):4978.
19. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468(7325):839-43.
20. Schlenk RF, Dohner K, Mack S, Stoppel M, Kiraly F, Gotze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010;28(30):4642-8.
21. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114(1):144-7.
22. Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2013;27(5):1044-52.
23. Itzykson R, Kosmider O, Cluzeau T, De Mas V, Dreyfus F, Quesnel B, et al. Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS. ASH Annual Meeting Abstracts 2010;116(21):439.
Published
2018-06-26
Issue
Vol 2 No 2 (2018)
Section
Original Article
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).